Trial reportNeurosurgery2026
Enhancing Asleep Deep Brain Stimulation Targeting for Essential Tremor Using Machine Learning: The OPTIVIM Phase 2 Study.
Trial report in Neurosurgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03760406 (Optimization of VIM Targeting in Essential Tremor Surgery), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Optimization of VIM Targeting in Essential Tremor Surgery
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
BACKGROUND AND
objectivesDeep brain stimulation (DBS) is an effective treatment of essential tremor, but the optimal target and how to reach it with the best accuracy remain controversial. The OptimDBS algorithm is based on Kernel Ridge Regression and was trained on a database of patients who underwent DBS with optimal postoperative outcomes. Using 3-dimensional T1-weighted MRI as the only input, it calculates the stereotactic coordinates of an effective DBS target for treating tremor. The aim of the study was to evaluate the efficacy and safety of OptimDBS-guided asleep DBS without peroperative clinical and electrophysiological controls in an independent cohort of patients.
methodsThe OPTIVIM study was a prospective, single-arm, multicenter Phase 2 trial. The primary outcome was tremor reduction and improvement in activities of daily living as assessed by the Fahn-Tolosa-Marin scale 3 months after surgery. Secondary outcomes included reduction in tremor amplitude on accelerometry, quality of life (modified Parkinson's Disease Questionnaire-39), ataxia (Scale for the Assessment and Rating of Ataxia), adverse events, and anatomic location of active contacts and the volume of tissue activated, all measured 3 months after surgery.
resultsTwenty-two patients from 2 centers were enrolled. Fahn-Tolosa-Marin scores improved by 61.3% (95% CI: 53.7%-68.9%). Accelerometry (mean ± SD) showed a reduction in postural tremor amplitude of 81% ± 56% on the right side and 84% ± 35% on the left side. Modified Parkinson's Disease Questionnaire-39 scores (median [Q1-Q3]) improved by 55% [24.3%-77.8%]. Scale for the Assessment and Rating of Ataxia scores remained stable (median [Q1-Q3], preoperative vs postoperative: 4 [3-6] vs 3 [2-6]). There were no serious adverse events. Active contacts were located in the posterior subthalamic area (59%) or the ventral-intermediate nucleus of the thalamus (20%), with 100% of volume of tissue activated overlapping the ventral-intermediate nucleus of the thalamus or posterior subthalamic area.
conclusionThe results of OptimDBS-guided asleep DBS seem to be comparable with those reported in the literature for awake and asleep DBS and ablative techniques. Long-term evaluations with larger cohorts are needed to confirm these results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.